AENEAS: A Randomized Phase III Trial of Aumolertinib Versus Gefitinib as First-Line Therapy for Locally Advanced or MetastaticNon–Small-Cell Lung Cancer With EGFR Exon 19 Deletion or L858R Mutations | Zendy

Shun Lü | Zendy; Xiaorong Dong | Zendy; Hong Jian | Zendy; Jianhua Chen | Zendy; Gongyan Chen | Zendy; Yuping Sun | Zendy; Yinghua Ji | Zendy; Ziping Wang | Zendy; Jianhua Shi | Zendy; Junguo Lu | Zendy; Shaoshui Chen | Zendy; Dongqing Lv | Zendy; Guojun Zhang | Zendy; Chunling Liu | Zendy; Juan Li | Zendy; Xinmin Yu | Zendy; Zhong Lin | Zendy; Zhuang Yu | Zendy; Zhehai Wang | Zendy; Jiuwei Cui | Zendy; Xingxiang Xu | Zendy; Jian Fang | Zendy; Jifeng Feng | Zendy; Zhixiang Xu | Zendy; Rui Ma | Zendy; Jie Hu | Zendy; g Yang | Zendy; Xiangdong Zhou | Zendy; Xiaohong Wu | Zendy; Chengping Hu | Zendy; Zhihong Zhang | Zendy; You Lü | Zendy; Yanping Hu | Zendy; Liyan Jiang | Zendy; Qiming Wang | Zendy; Renhua Guo | Zendy; Jianying Zhou | Zendy; Baolan Li | Zendy; Chunhong Hu | Zendy; Wan-cheng Tong | Zendy; Helong Zhang | Zendy; Lin Ma | Zendy; Yuan Chen | Zendy; Zhijun Jie | Zendy; Yu Yao | Zendy; Longzhen Zhang | Zendy; Jie Weng | Zendy; Weidong Li | Zendy; Jianping Xiong | Zendy; Xianwei Ye | Zendy; Jianchun Duan | Zendy; Haihua Yang | Zendy; Meili Sun | Zendy; Changan Sun | Zendy; Hongying Wei | Zendy; Chuan Li | Zendy; Siraj M. Ali | Zendy; Vincent A. Miller | Zendy; Qiong Wu | Zendy

Open Access

AENEAS: A Randomized Phase III Trial of Aumolertinib Versus Gefitinib as First-Line Therapy for Locally Advanced or MetastaticNon–Small-Cell Lung Cancer With EGFR Exon 19 Deletion or L858R Mutations

Author(s) -

Shun Lü,

Xiaorong Dong,

Hong Jian,

Jianhua Chen,

Gongyan Chen,

Yuping Sun,

Yinghua Ji,

Ziping Wang,

Jianhua Shi,

Junguo Lu,

Shaoshui Chen,

Dongqing Lv,

Guojun Zhang,

Chunling Liu,

Juan Li,

Xinmin Yu,

Zhong Lin,

Zhuang Yu,

Zhehai Wang,

Jiuwei Cui,

Xingxiang Xu,

Jian Fang,

Jifeng Feng,

Zhixiang Xu,

Rui Ma,

Jie Hu,

g Yang,

Xiangdong Zhou,

Xiaohong Wu,

Chengping Hu,

Zhihong Zhang,

You Lü,

Yanping Hu,

Liyan Jiang,

Qiming Wang,

Renhua Guo,

Jianying Zhou,

Baolan Li,

Chunhong Hu,

Wan-cheng Tong,

Helong Zhang,

Lin Ma,

Yuan Chen,

Zhijun Jie,

Yu Yao,

Longzhen Zhang,

Jie Weng,

Weidong Li,

Jianping Xiong,

Xianwei Ye,

Jianchun Duan,

Haihua Yang,

Meili Sun,

Changan Sun,

Hongying Wei,

Chuan Li,

Siraj M. Ali,

Vincent A. Miller,

Qiong Wu

Publication year - 2022

Publication title -

journal of clinical oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 10.482

H-Index - 548

eISSN - 1527-7755

pISSN - 0732-183X

DOI - 10.1200/jco.21.02641

Subject(s) - gefitinib , medicine , hazard ratio , lung cancer , rash , clinical endpoint , epidermal growth factor receptor , oncology , gastroenterology , randomized controlled trial , cancer , confidence interval

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research